TransCode Therapeutics, Inc. has announced the offering of common stock, pre-funded warrants to purchase common stock, and shares of common stock issuable upon the exercise of pre-funded warrants. The offering is detailed in a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act. The prospectus supplement, dated July 22, 2024, outlines the terms of the offering, including the purchase price of shares and pre-funded warrants, the immediate exercisability of the pre-funded warrants, and the lack of an established trading market for the pre-funded warrants. TransCode has engaged ThinkEquity LLC as the exclusive placement agent for the offering, which is on a best-efforts basis with no minimum offering requirement. The proceeds are intended for product development activities, clinical trials, working capital, and other general corporate purposes. The offering is expected to close on or about July, 2024, subject to customary closing conditions.

TransCode Therapeutics, Inc. has announced the offering of common stock, pre-funded warrants to purchase common stock, and shares of common stock issuable upon the exercise of pre-funded warrants. The offering is detailed in a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act. The prospectus supplement, dated July 22, 2024, outlines the terms of the offering, including the purchase price of shares and pre-funded warrants, the immediate exercisability of the pre-funded warrants, and the lack of an established trading market for the pre-funded warrants. TransCode has engaged ThinkEquity LLC as the exclusive placement agent for the offering, which is on a best-efforts basis with no minimum offering requirement. The proceeds are intended for product development activities, clinical trials, working capital, and other general corporate purposes. The offering is expected to close on or about July, 2024, subject to customary closing conditions.